Anti-idiotypic antibody (Ab2) vaccines: Coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue SUPPL. 2, 2001, Pages

  Birebent, Brigitte ^a   Koido, Takashi ^a   Mitchell, Edith ^b   Li, Weiping ^a   Somasundaram, Rajasekharan ^a   Purev, Enkhtsetseg ^a   Hoey, Diane ^b   Mastrangelo, Michael ^b   Maguire, Henry ^b   Harris, David T ^c   Nair, Sridhar ^a   Cai, Dewei ^a   Herlyn, Dorothee ^a  

^a WISTAR INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LANKENAU HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HEMOCYANIN; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; TUMOR ANTIGEN;

ANIMAL; ANTIBODY PRODUCTION; ARTICLE; COLORECTAL TUMOR; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; RABBIT; RAT;

ANIMAL; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; COLORECTAL NEOPLASMS; HEMOCYANIN; HUMAN; IMMUNIZATION; IMMUNOGLOBULIN IDIOTYPES; LYMPHOCYTE ACTIVATION; RABBITS; RATS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035491503     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01470996     Document Type: Article

References (32)

1. Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76: 1438-1442
2. Bumol TF, Marder P, DeHerdt SV, Borowitz MJ, Apelgren LD (1988) Characterization of the human tumor and normal tissue reactivity of the KS1/4. Hybridoma 7: 407-415
3. Litvinov SV, Velders MP, Bakker HAM, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125: 437-446
4. Mach JP, Chatal JF, Lumbroso JD, Buchegger F, Forni M, Ritschard J, Berche C, Douillard JY, Carrel S, Herlyn M, Steplewski Z, Koprowski H (1983) Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 43: 5593-5600
5. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber P, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788-1794
6. Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M, Koprowski H (1987) Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 84: 8055-8059
7. Loibner H, Plot R, Rot A, Werner G, Wrann M, Samonigg H, Schmid M, Stoger H, Truschnig M, Herlyn D, Koprowski H (1990) Immunoreactivity of patient with colorectal cancer metastasis after immunization with anti-idiotypes. Lancet 335: 171
8. Samonigg H, Wilders-Truschnig M, Loibner H, Plot R, Rot A, Kuss I, Werner G, Stoger H, Wrann M, Herlyn D, Koprowski H (1992) Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody. Clin Immunol Immunopathol 65: 271-277
9. Herlyn D, Harris D, Zaloudik J, Sperlagh M, Maruyama H, Jacob L, Kieny M-P, Scheck S, Somasundaram R, Hart E, Ertl H, Mastrangelo M (1994) Immunoregulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J Immunother 15: 303-311
10. Herlyn D, Benden A, Kane M, Somasundaram R, Zaloudik J, Sperlagh M, Marks G, Hart E, Ralph C, Wettendorff M, Mastrangelo M (1991) Anti-idiotype cancer vaccines: preclinical and clinical studies. In Vivo 5: 615-623
11. Somasundaram R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, Marks G, Mastrangelo M, Herlyn D (1995) Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 155: 3253-3261
12. Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies Proc Natl Acad Sci USA 76: 1438-1442
13. Herlyn D, Herlyn M, Ross AH, Ernst C, Atkinson B, Koprowski H (1984) Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 73: 157-167
14. Koido T, Scheck C, Herlyn D (1995) Induction of immunity to colon carcinoma antigen CO17-1A by monoclonal anti-idiotype (Ab2): effects of Ab2 fragmentation, carrier and adjuvant. Tumor Targeting 1: 115-124
15. Birebent B, Mitchell E, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris D, Nair S, Cai D, Herlyn D (2001) Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Clin Cancer Res (in press)
16. Strassburg CP, Kasai Y, Seng BA, Miniou P, Zaloudik J, Herlyn D, Koprowski H, Linnenbach AJ (1992) Baculovirus recombinant expressing a secreted form of a trans-membrane carcinoma-associated antigen. Cancer Res 52: 815-821
17. Herlyn M, Koprowski H (1988) Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol 6: 283-308
18. Wettendorff M, Iliopoulos D, Schmoll E, Koprowski H, Herlyn D (1989) Specific detection of antibodies in cancer patients following immunotherapy with anti-idiotype. J Immunol Meth 116: 105-115
19. Ross AH, Herlyn D, Iliopoulos D, Koprowski H (1986) Isolation and characterization of a carcinoma-associated antigen. Biochem Biophys Res Commun 135: 297-303
20. GØttlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G (1986) The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38: 47-53
21. Hirshaut Y, Slovin F (1985) Harnessing T-lymphocytes for human cancer immunotherapy. Cancer 56: 1366-1373
22. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1994) Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight melanoma-associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 54: 415-421
23. Foon KA, Sen G, Hutchins L, Kashala O, Baral R, Banerjee M, Chakraborty M, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M (1998) Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 4: 1117-1124
24. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB (1999) Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 5: 77-81
25. Durrant LG, Bukley DJ, Spendlove I, Robins RA (1997) Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity. Hybridoma 16: 23-26
26. Foon KA, John WJ, Chakraborty M, Sherratt A, Garrison J, Flett M, Bhattacharya-Chatterjee M (1997) Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 3: 1267-1276
27. Foon KA, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Berstein Z, Pincus S, Kohler H, Seon BK, Tahaoglu E, Beers T, Chakraborty M, Bhattacharya-Chatterjee M (1995) Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res 1: 1285-1294
28. Hamby CV, Liao SK, Kanamuru T, Ferrone S (1987) Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. Cancer Res 47: 5283-5289
29. Birebent B, Somasundaram R, Purev E, Li W, Mitchell E, Hoey D, Bloom E, Mastrangelo M, Maguire C, Harris DT, Staib L, Braumuller H, Leeser C, Kuttner N, Beger H-G, Herlyn D (2001) Anti-idiotypic antibody and recombinant vaccines in colorectal cancer patients. Crit Rev Oncol Hematol 39: 107-113
30. Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D (2000) Cancer vaccines: single epitope anti-idiotype vaccine versus multiple epitope antigen vaccine. Cancer Immunol Immunother 49: 123-132
31. Li W, Berencsi K, Basak S, Somasundaram R, Ricciardi RP, Gonczol E, Zaloudik J, Linnenbach A, Maruyama H, Miniou P, Herlyn D (1997) Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by recombinant adenovirus inhibits growth of established CRC cells in mice. J Immunol 159: 763-769
32. Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D (2000) Colorectal cancer vaccines: anti-idiotypic antibody, recombinant protein, and viral vector. Ann NY Acad Sci 910: 237-253